CEBPA and metabolic dysfunction-associated steatotic liver disease: RBTP and bezafibrate were able to significantly inhibit the down-regulation of LPL, PPAR-α, CYP7A1, and CPT1 expression and the up-regulation of PPAR-γ and C/EBP-α in liver tissue of NAFLD mice (p < 0.05).